Skip to main content
SpringerLink
Log in

Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Hepatocellular carcinoma (HCC) is a common malignancy in Asians with hepatitis B virus infection. HCC patients often present with poor liver function and large tumors resulting in rapid mortality. The impact of HCC surveillance and subsequent therapy on patient survival remain controversial.

Aims

We sought to determine if surveillance for HCC in a community-based clinic improve survival and, if so, identify factors that contribute to the benefit of early tumor detection.

Methods

From 1991 to 2008, alpha-fetoprotein and abdominal ultrasound examination were used as surveillance tests for HCC. The survival of HCC patients detected by surveillance was compared to patients who presented to the clinic with HCC (no surveillance). An adjusted lead-time bias interval was added to the survival time of patients who presented with HCC.

Results

During this period, 26 patients with surveillance developed HCC while 52 patients presented with HCC. More surveillance patients had normal levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase (p < 0.05–0.0001) and had tumors that were within Milan and University of California San Francisco (UCSF) criteria (p = 0.02–0.0001). The 1-, 3-, and 5-year survival rates were higher in surveillance patients and in those who received surgical or loco-regional therapies (p = 0.007–0.0001). On multivariate analysis, baseline independent factors predicting survival were single tumors (Hazard ratio [HR] 0.25, p = 0.0005), UCSF criteria (HR 0.29, p = 0.006), Child-Turcotte-Pugh class A (HR 0.45, p = 0.03), platelet counts per log10 increase (HR 0.315, p = 0.04) and aspartate aminotransferase per log10 increase (HR 5.7, p = 0.01).

Conclusions

Surveillance for HCC identified patients with smaller tumor burdens and more adequate liver function who were able to receive more definitive therapies. HCC surveillance improves survival and should be included as standard of care for patients with hepatitis B.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

HCC:

Hepatocellular carcinoma

HBV:

Hepatitis B virus

AFP:

Alpha-fetoprotein

UCSF:

University of California San Francisco

CTP:

Child-Turcotte-Pugh scoring system

AST:

Aspartate aminotransferase

AST:

Alanine aminotransferase

HR:

Hazard ratio

References

  1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543.

    Article  CAS  PubMed  Google Scholar 

  2. El-Serag HB, Rudolph LK. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.

    Article  CAS  PubMed  Google Scholar 

  3. Han KH, Kim JK. Liver cancer in Korea. Hepatol Res. 2007;37(2):S106–S109.

    Article  PubMed  Google Scholar 

  4. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomized controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.

    Article  PubMed  Google Scholar 

  5. Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–691.

    Article  PubMed  Google Scholar 

  6. Barazani Y, Hiatt JR, Tong MJ, et al. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg. 2007;31:1243–1248.

    Article  PubMed  Google Scholar 

  7. Tong MJ, Chavalitdhamrong D, Lu DSK, et al. Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA. J Clin Gastroenterol. 2009 (in press).

  8. Di Biscelglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98(9):2060–2063.

    Google Scholar 

  9. Alterkruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, morality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–1491.

    Article  Google Scholar 

  10. McCracken M, Olsen M, Chen MS Jr, et al. Cancer incidence, mortality and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean and Japanese ethnicities. CA Cancer J Clin. 2007;57:190–205.

    Article  PubMed  Google Scholar 

  11. Chlebowski RT, Tong M, Weissman J, et al. Hepatocellular carcinoma: diagnostic and prognostic features in North American patients. Cancer. 1984;53:2701–2706.

    Article  CAS  PubMed  Google Scholar 

  12. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer. 1996;77:2217–2222.

    Article  CAS  PubMed  Google Scholar 

  13. Geller DA, Tsung A, Wallis Marsh J, et al. Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. J Gastrointest Surg. 2006;10:63–68.

    Article  PubMed  Google Scholar 

  14. Hwang JP, Hassan MM. Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer. 2009;9:46.

    Article  PubMed  Google Scholar 

  15. Wong GLH, Wong VWS, Tan GM, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28(1):79–87.

    CAS  PubMed  Google Scholar 

  16. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.

    PubMed  Google Scholar 

  17. Mok TSK, Yeo W, Yu S, et al. An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol. 2005;23(31):8041–8047.

    Article  PubMed  Google Scholar 

  18. Chen THH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98:257–261.

    Article  CAS  PubMed  Google Scholar 

  19. Mima S, Sekiya C, Kanagawa H, et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol. 1994;9:361–365.

    Article  CAS  PubMed  Google Scholar 

  20. Toyoda H, Kumada T, Kiriyama S, et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol. 2006;4:1170–1176.

    Article  PubMed  Google Scholar 

  21. Adams PC, Arthur MJ, Boyer TD, et al. Screening in liver disease: report of an AASLD clinical workshop. Hepatology. 2004;39:1204–1212.

    Article  PubMed  Google Scholar 

  22. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272–1294.

    Article  CAS  PubMed  Google Scholar 

  23. El-Serag HB, Lau M, Eschbach K, et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med. 2007;167(18):1983–1989.

    Article  PubMed  Google Scholar 

  24. Tong MJ, Sun SC, Schaeffer BT, et al. Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med. 1971;75:687–691.

    CAS  PubMed  Google Scholar 

  25. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut. 2001;48:251–259.

    Article  CAS  PubMed  Google Scholar 

  26. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma during surveillance. Gastroenterology. 2004;126:1005–1014.

    Article  PubMed  Google Scholar 

  27. Trevisani F, Magini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102:1022–1031.

    Article  PubMed  Google Scholar 

  28. Pasqual S, Irurzun J, Zapater P, et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. Liver Int. 2008;28(5):682–689.

    Google Scholar 

  29. Hwang SJ, Tong MJ, Lai PPC, et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol. 1996;11:949–954.

    CAS  PubMed  Google Scholar 

  30. Tong MJ, Blatt LM, Kao JH, et al. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol. 2006;12(41):6620–6626.

    CAS  PubMed  Google Scholar 

  31. Tong MJ, Blatt LM, Kao JH, et al. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int. 2007;27(10):1356–1363.

    CAS  PubMed  Google Scholar 

  32. Yang HI, Yeh SH, Chen PJ, et al. Association between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1134–1143.

    Article  CAS  PubMed  Google Scholar 

  33. Yuen MF, Tanaka Y, Fong DYT, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–88.

    Article  PubMed  Google Scholar 

  34. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22:432–438.

    CAS  PubMed  Google Scholar 

  35. Tong MJ, Blatt LM, Kao VWC. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16:553–559.

    Article  CAS  PubMed  Google Scholar 

  36. Barbara L, Nemzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16:132–137.

    Article  CAS  PubMed  Google Scholar 

  37. Kubota K, Ina H, Okada Y, et al. Growth rate of primary single hepatocellular carcinoma: determine optimal screening interval with contrast enhanced computed tomography. Digest Dis Sci. 2003;48(3):581–586.

    Article  PubMed  Google Scholar 

  38. Okada S, Okazaki N, Nose H. Follow-up examination schedule of postoperative HCC patients based on tumor volume doubling time. Hepato-Gastroenterol. 1993;40:311–315.

    CAS  Google Scholar 

  39. Yoshino M. Growth kinetics of hepatocellular carcinoma. Jpn J Clin Oncol. 1983;13(1):45–52.

    CAS  PubMed  Google Scholar 

  40. Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985;89:259–266.

    CAS  PubMed  Google Scholar 

  41. Farianati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost effective? Eur J Cancer Prev. 2001;10:111–115.

    Article  Google Scholar 

  42. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded. Ann Surg. 2007;246:502–511.

    Article  PubMed  Google Scholar 

  43. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Jeffery A. Gornbein, Dr. PH and Rebecca Radbod, MPH for their statistical expertise.

Author information

Authors and Affiliations

  1. The Liver Center, Huntington Medical Research Institutes, 660 S. Fair Oaks Ave, Pasadena, CA, 91105, USA

    Myron J. Tong, Hai-En Sun & Carlos Hsien

  2. Pfleger Liver Institute at UCLA, Los Angeles, CA, USA

    Myron J. Tong

  3. Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Myron J. Tong

  4. Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    David S. K. Lu

Authors
  1. Myron J. Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hai-En Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos Hsien
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David S. K. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Myron J. Tong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tong, M.J., Sun, HE., Hsien, C. et al. Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic. Dig Dis Sci 55, 826–835 (2010). https://doi.org/10.1007/s10620-009-1059-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-009-1059-y

Keywords

Search

Navigation